Mercer Global Advisors’s ADMA Biologics ADMA Stock Holding History

Mercer Global Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$403K	Buy	48,135 +36,496	+314%	+$333K	﹤0.01%	2498
2026 Q1	$105K	Buy	+11,639	New	+$184K	﹤0.01%	3005
2024 Q1	–	Sell	-15,500	Closed	-$70K	–	1950
2023 Q4	$70K	Sell	15,500 -200	-1%	-$740	﹤0.01%	1936
2023 Q3	$56K	Buy	15,700 +700	+5%	+$2.69K	﹤0.01%	1890
2023 Q2	$55K	Hold	15,000	–	–	﹤0.01%	1866
2023 Q1	$50K	Hold	15,000	–	–	﹤0.01%	1868
2022 Q4	$58K	Hold	15,000	–	–	﹤0.01%	1854
2022 Q3	$36K	Hold	15,000	–	–	﹤0.01%	1784
2022 Q2	$30K	Buy	+15,000	New	+$29.5K	﹤0.01%	1786

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mercer Global Advisors's ADMA Position: Q2 2026 in Review

Mercer Global Advisors increased its ADMA Biologics (ADMA) stake by 314% in Q2 2026, buying an estimated $333K and bringing the position to 48,135 shares worth $403K. The position accounts for ﹤0.01% of the portfolio, ranked #2498.

Mercer Global Advisors first reported a position in ADMA in Q2 2022 and has held it in 9 quarters since. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Mercer Global Advisors held 48,135 shares of ADMA Biologics worth $403K as of Q2 2026.
Mercer Global Advisors bought 36,496 ADMA Biologics shares in Q2 2026, an estimated $333K.
ADMA Biologics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2498 holding.
Mercer Global Advisors first reported a position in ADMA Biologics in Q2 2022 and has held it in 9 quarters since.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.